<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vortioxetine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vortioxetine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vortioxetine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="91147" href="/d/html/91147.html" rel="external">see "Vortioxetine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F21988322"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behaviors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Vortioxetine is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F22152240"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trintellix</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871655"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Trintellix</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F21988325"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant, Selective Serotonin Reuptake Inhibitor/5-HT<sub>1A</sub> Receptor Partial Agonist;</li>
<li>
                        Serotonin 5-HT<sub>3</sub> Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F22560981"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (alternative agent):</b>
<b>Oral:</b> Initial: 5 to 10 mg once daily; may increase daily dose based on response and tolerability in increments of 5 to 10 mg at ≥1-week intervals up to target dose of 20 mg once daily (usual maximum dose: 20 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21767441','lexi-content-ref-24165478','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21767441','lexi-content-ref-24165478','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maximum dose in known CYP2D6 poor metabolizers: </i>10 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Discontinuation of therapy:</i></b> The half-life of vortioxetine is significantly greater than 24 hours, decreasing the risk of withdrawal symptoms. Although few withdrawal symptoms due to abrupt discontinuation of vortioxetine have been described, it is recommended that patients receiving 15 or 20 mg/day be tapered to 10 mg/day for 1 week before full discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2021a','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2021a','lexi-content-ref-Manu.1'])">Ref</a></span>). Patients with a prior history of antidepressant withdrawal symptoms or on a high dose may require a slower taper (eg, over 4 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2021a'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Switching antidepressants: </i></b>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks, depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches but is contraindicated when switching to or from a monoamine oxidase inhibitor (MAOI). A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between a selective serotonin reuptake inhibitor and vortioxetine), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2021b','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2021b','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of vortioxetine.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 21 days to elapse between discontinuing vortioxetine and initiation of an MAOI. Due to prolonged washout in patients who are obese (BMI ≥35 kg/m<sup>2</sup>), consider allowing 32 days to elapse between discontinuing vortioxetine and initiating an MAOI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29596146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29596146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990144"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987486"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doo drugH1Div" id="F54001977"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">Refer to situation-specific dosing for obesity-related information (may not be available for all indications).</p></div>
<div class="block doe drugH1Div" id="F22560982"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Oral: Initial: 5 mg once daily; may increase to 10 mg once daily as tolerated. Use caution with doses &gt;10 mg daily (maximum: 20 mg/day).</p></div>
<div class="block arsc drugH1Div" id="F56294641"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. A mixed/manic mood switch has been reported in a patient receiving vortioxetine who was also receiving maintenance medications for bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26994277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26994277'])">Ref</a></span>). Treatment-emergent <b>mania</b> or <b>hypomania </b>has also been reported rarely in patients with unipolar major depressive disorder (MDD) receiving vortioxetine, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aydin.2019','lexi-content-ref-26864543','lexi-content-ref-31328985','lexi-content-ref-28273272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aydin.2019','lexi-content-ref-26864543','lexi-content-ref-31328985','lexi-content-ref-28273272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; among the limited case reports involving vortioxetine, the time until onset of mania/hypomania following initiation or a dose increase varied from 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aydin.2019','lexi-content-ref-31328985','lexi-content-ref-26994277','lexi-content-ref-28273272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aydin.2019','lexi-content-ref-31328985','lexi-content-ref-26994277','lexi-content-ref-28273272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Antidepressants in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonergic antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants. Vortioxetine, a multimodal antidepressant with serotonergic activity, may also increase the risk of bleeding, although data are limited. For SSRIs, multiple observational studies have found an association with SSRI use and a variety of bleeding complications, although prospective studies have not determined if the cause of the increased risk of bleeding is due to SSRI use alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645','lexi-content-ref-28257449','lexi-content-ref-29536379','lexi-content-ref-25562777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645','lexi-content-ref-28257449','lexi-content-ref-29536379','lexi-content-ref-25562777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> SSRIs are believed to affect bleeding via inhibition of serotonin-mediated platelet activation (inhibition of the reuptake of serotonin into platelets leading to depletion of platelet serotonin thereby resulting in subsequent platelet dysfunction). Vortioxetine’s mechanism has not been fully elucidated but is believed to be multimodal with inhibition of serotonin (5-HT) reuptake and via direct modulation of various serotonin receptors as a 5-HT<sub>3</sub>, 5-HT<sub>7</sub> and 5-HT<sub>1D</sub> receptor antagonist, a 5-HT<sub>1B</sub> partial agonist, and a 5HT<sub>1A</sub> agonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26864543','lexi-content-ref-30081645','lexi-content-ref-25628505','lexi-content-ref-29536379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26864543','lexi-content-ref-30081645','lexi-content-ref-25628505','lexi-content-ref-29536379'])">Ref</a></span>). Vortioxetine is hypothesized to have high serotonin transporter binding affinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; based on data evaluating SSRIs, it has been suggested that the onset of risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>), although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of antiplatelets and/or anticoagulants (based on SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-12523917','lexi-content-ref-18606952','lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-12523917','lexi-content-ref-18606952','lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of NSAIDs (based on SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151','lexi-content-ref-12523917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151','lexi-content-ref-12523917'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (based primarily on SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18606952','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18606952','lexi-content-ref-17506225'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly older adults (≥50 years of age) suggest antidepressant use may be associated with an increased risk of bone fractures. The antidepressants evaluated in the literature predominantly involve the selective serotonin reuptake inhibitors (SSRIs) and the tricyclic antidepressants (TCAs), followed to a lesser extent by the serotonin norepinephrine reuptake inhibitors (SNRIs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21810375','lexi-content-ref-30247774','lexi-content-ref-24566587','lexi-content-ref-22638709','lexi-content-ref-26032210','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-30964616','lexi-content-ref-26126579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21810375','lexi-content-ref-30247774','lexi-content-ref-24566587','lexi-content-ref-22638709','lexi-content-ref-26032210','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-30964616','lexi-content-ref-26126579'])">Ref</a></span>). To date, data are too limited to determine whether an association with fractures and vortioxetine, a multimodal antidepressant with serotonergic activity, exists although a rare case of <b>stress fracture </b>has been observed with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25575488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25575488'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; based on mostly SSRI-derived literature, the mechanism has not been fully elucidated, although postulated to be through a direct effect by serotonergic agents on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24566587','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24566587','lexi-content-ref-30775508'])">Ref</a></span>). SSRIs may also contribute to fall risk, contributing to the incidence of fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27495351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27495351'])">Ref</a></span>). Of note, data are too limited to determine whether an association exists with vortioxetine and fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; using data on mostly SSRI-derived literature, risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>). Of note, data are too limited to determine whether an association exists with vortioxetine and fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Long-term use (potential risk factor) (SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>). Of note, data are too limited to determine whether an association exists with vortioxetine and fractures.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (selective serotonin reuptake inhibitors [SSRIs] most commonly) are associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and/or <b>hyponatremia </b>(including severe cases), predominantly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-27773479','lexi-content-ref-27194321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-27773479','lexi-content-ref-27194321'])">Ref</a></span>). Hyponatremia has been reported rarely with vortioxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25628505','lexi-content-ref-28844296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25628505','lexi-content-ref-28844296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antidepressants may cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026','lexi-content-ref-28844296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026','lexi-content-ref-28844296'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; based on data involving SSRIs, hyponatremia usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026','lexi-content-ref-27194321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026','lexi-content-ref-27194321'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Based on data involving SSRIs, risk factors include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of hyponatremia (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Symptoms of psychosis (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (selective serotonin reuptake inhibitors [SSRIs] and serotonin norepinephrine reuptake inhibitors [SNRIs] most commonly implicated) are associated with acute angle-closure glaucoma (AACG) in case reports. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15746956','lexi-content-ref-27993931','lexi-content-ref-30278181','lexi-content-ref-29893371']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15746956','lexi-content-ref-27993931','lexi-content-ref-30278181','lexi-content-ref-29893371'])">Ref</a></span>). Data are too limited to determine if vortioxetine, a multimodal antidepressant with serotonergic activity, is associated with an increased risk for AACG.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear; hypothesized that serotonergic antidepressants like SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28257449','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28257449','lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Based on SSRI- and SNRI-derived literature:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• ≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported with serotonergic agents, including rarely with vortioxetine, and typically occurs with coadministration of multiple serotonergic drugs. There is also a case report of serotonin syndrome occurring in a patient receiving vortioxetine at therapeutic doses and without any concomitant serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29917334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29917334'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in most serotonin-syndrome cases (74%) (predominantly involving selective serotonin reuptake inhibitors, tricyclic antidepressants, and/or monoamine oxidase inhibitors [MAOIs]), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism (eg, MAOIs). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (potential risk factor due to the prolongation of half-life observed in individuals with obesity compared to individuals without obesity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29596146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29596146'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants, primarily the selective serotonin reuptake inhibitors (SSRIs), are commonly associated with <b>male sexual disorder </b>and <b>female sexual disorder</b>. Vortioxetine, a multimodal antidepressant with serotonergic activity, is typically associated with either low rates of treatment-emergent sexual dysfunction or incidences comparable to placebo in the few clinical trials available. In addition, limited data suggest that vortioxetine may have some beneficial effects on sexual functioning in depressed patients who switched from an antidepressant with high rates of dysfunction to vortioxetine. However, treatment-emergent sexual dysfunction is typically underreported and clinical benefit on sexual functioning is difficult to ascertain in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26864543','lexi-content-ref-27508501','lexi-content-ref-28245753','lexi-content-ref-26020712','lexi-content-ref-26331383','lexi-content-ref-26575433','lexi-content-ref-31405765','lexi-content-ref-31010445','lexi-content-ref-29955469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26864543','lexi-content-ref-27508501','lexi-content-ref-28245753','lexi-content-ref-26020712','lexi-content-ref-26331383','lexi-content-ref-26575433','lexi-content-ref-31405765','lexi-content-ref-31010445','lexi-content-ref-29955469'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism attributed to vortioxetine’s role (if any) in sexual dysfunction is unknown; however, using literature involving SSRIs, it has been postulated that increases in serotonin may affect other hormones and neurotransmitters involved in sexual function. Vortioxetine is a multimodal antidepressant with serotonergic activity through direct modulation of 5-HT receptors and inhibition of serotonin reuptake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31010445','lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31010445','lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; antidepressant-induced sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking/behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years) in short-term studies. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age, a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26864543','lexi-content-ref-25693810','lexi-content-ref-17485726','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-31199210','lexi-content-ref-29923970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26864543','lexi-content-ref-25693810','lexi-content-ref-17485726','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-31199210','lexi-content-ref-29923970'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms, leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to longer-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability, mania), have been reported with serotonergic antidepressants, primarily following abrupt discontinuation. Withdrawal symptoms may also occur following gradual tapering. In general, antidepressant discontinuation symptoms usually last a few weeks, but occasionally may persist for months or possibly even years (ie, persistent postwithdrawal disorder) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26864543','lexi-content-ref-27508501','lexi-content-ref-25721705','lexi-content-ref-30016772','lexi-content-ref-28554948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26864543','lexi-content-ref-27508501','lexi-content-ref-25721705','lexi-content-ref-30016772','lexi-content-ref-28554948'])">Ref</a></span>). Data from clinical trials and observational data with vortioxetine specifically suggest that discontinuation symptoms may occur, particularly with abrupt withdrawal, but the incidence is low and/or similar to placebo, possibly due to its relatively long half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26864543','lexi-content-ref-25575488','lexi-content-ref-29238196','lexi-content-ref-34064611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26864543','lexi-content-ref-25575488','lexi-content-ref-29238196','lexi-content-ref-34064611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the serotonergic agent. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in literature derived from selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors discontinuation, symptom onset usually occurs within a few days after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30016772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30016772'])">Ref</a></span>). In a small number of patients (n=8) from the retrospective chart review of vortioxetine experiencing discontinuation symptoms (primarily those who discontinued therapy without medical consultation), onset was 3 days following therapy withdrawal and symptoms lasted for a median of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34064611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34064611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted for &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972','lexi-content-ref-Hirsch.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972','lexi-content-ref-Hirsch.2021a'])">Ref</a></span>). Of note, vortioxetine has a long half-life (~66 hours in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26864543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26864543'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2021a'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34064611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34064611'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F22132809"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (21% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Female sexual disorder (≤2%; Arizona Sexual Experiences Scale: 22% to 34%)<span class="lexi-table-link-container"> (<a aria-label="Female Sexual Disorder table link" class="lexi-table-link" data-table-id="lexi-content-female-sexual-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-female-sexual-disorder')">table 1</a>)</span><span class="table-link" style="display:none;">Female Sexual Disorder</span>, male sexual disorder (3% to 5%; Arizona Sexual Experiences Scale: 16% to 29%)<span class="lexi-table-link-container"> (<a aria-label="Male Sexual Disorder table link" class="lexi-table-link" data-table-id="lexi-content-male-sexual-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-male-sexual-disorder')">table 2</a>)</span><span class="table-link" style="display:none;">Male Sexual Disorder</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Female Sexual Disorder" frame="border" id="lexi-content-female-sexual-disorder" rules="all">
<caption style="text-align:center;">
<b>Vortioxetine: Adverse Reaction: Female Sexual Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vortioxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vortioxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">699</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">449</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">67</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">57</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Male Sexual Disorder" frame="border" id="lexi-content-male-sexual-disorder" rules="all">
<caption style="text-align:center;">
<b>Vortioxetine: Adverse Reaction: Male Sexual Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vortioxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vortioxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">449</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">699</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,013</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,621</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">59</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">67</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">67</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arizona Sexual Experiences Scale</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (5% to 6%), diarrhea (7% to 10%), flatulence (2% to 3%), vomiting (3% to 6%), xerostomia (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (2% to 3%), dizziness (8% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypomania, mania</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Suicidal ideation, suicidal tendencies, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Mydriasis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (Işik 2022), hyperprolactinemia, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation, anosmia (including hyposmia), headache, hostility, irritability, outbursts of anger, restless leg syndrome (Romigi 2019), seizure, serotonin syndrome (Ong 2018), withdrawal syndrome (Baldwin 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Stress fracture (Mahableshwarkar 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (O’Brien 2023)</p></div>
<div class="block coi drugH1Div" id="F21988328"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, angioedema) to vortioxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 21 days of discontinuing vortioxetine or within 14 days of discontinuing the MAO inhibitor); initiation of vortioxetine in a patient receiving linezolid or intravenous methylene blue.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F22560964"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Major psychiatric warnings:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal thinking/behavior: Consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients ≥65 years of age. Instruct the patient's family or caregiver to closely observe the patient and communicate condition with health care provider, particularly during the first few months of therapy or during periods of dose adjustments. A medication guide concerning the use of antidepressants should be dispensed with each prescription.</p>
<p style="text-indent:-2em;margin-left:6em;">-The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">-Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Risk of postpartum bleeding may be increased with SSRI use, particularly in the month prior to delivery. Bleeding related to antidepressant use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda 2013; Rizzoli 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause mild pupillary dilation which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic antidepressants (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, meperidine, methadone, tramadol, buspirone, amphetamines, St John's wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>
<p style="text-indent:-2em;margin-left:4em;">• SIADH and hyponatremia: Serotonergic drugs have been associated with the development of SIADH; hyponatremia has been reported (including severe cases with serum sodium &lt;110 mmol/L). Age (the elderly), volume depletion and/or concurrent use of diuretics likely increases risk. Discontinue treatment in patients with symptomatic hyponatremia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Mania/hypomania: Screen patients for history or family history of bipolar disorder, mania, or hypomania prior to initiating therapy; may precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Combination therapy with an antidepressant and a mood stabilizer should also be avoided in acute mania or mixed episodes, as well as maintenance treatment in bipolar disorder due to the mood-destabilizing effects of antidepressants (CANMAT [Yatham 2018]; WFSBP [Grunze 2018]). Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Vortioxetine is not FDA approved for the treatment of bipolar depression.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with seizure disorders, a prior history of seizure disorder, or conditions predisposing to seizures; seizures (rare) have been reported in patients without a prior history of seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, lightheadedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddad 2001; Shelton 2001; Warner 2006).</p></div>
<div class="block foc drugH1Div" id="F22152241"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trintellix: 5 mg, 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F22152239"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613365"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Trintellix Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $19.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $19.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $19.59</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871656"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trintellix: 5 mg, 10 mg, 20 mg</p></div>
<div class="block adm drugH1Div" id="F22560986"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer without regard to meals.</p></div>
<div class="block meg drugH1Div" id="F22060179"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:2em;">Trintellix: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F204447s026lbl.pdf%23page%3D33&amp;token=3cX1Tmm%2F8CnqxGCOhWFR%2FqMvmdGt8z%2F7BignMDgQduc3wqPDNTHmSjIzeNYgLv68TSufqS0OTAksc5wZ%2BpSdzOe5%2BHhZL7aYczx9Hz%2FLb96hFfw7ECxnldJ8raz8Kks2&amp;TOPIC_ID=91014" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204447s026lbl.pdf#page=33</a></p></div>
<div class="block use drugH1Div" id="F21988327"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Major depressive disorder: </b>Treatment of major depressive disorder (MDD).</p></div>
<div class="block mst drugH1Div" id="F22560958"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vortioxetine may be confused with duloxetine, fluoxetine, paroxetine</p>
<p style="text-indent:-2em;margin-left:4em;">Brintellix may be confused with Brilinta</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F22061023"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F22061021"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the adverse/toxic effect of Vortioxetine. BuPROPion may increase the serum concentration of Vortioxetine. Management: The vortioxetine dose should be reduced by 50% when used together with bupropion. Following cessation of bupropion, the vortioxetine dose should be returned to the normal level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Citalopram may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Vortioxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Vortioxetine. Management: The vortioxetine dose should be reduced by 50% when used together with a strong CYP2D6 inhibitor. Following cessation of the strong CYP2D6 inhibitor, the vortioxetine dose should be returned to the normal level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Vortioxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Vortioxetine. Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of DULoxetine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Avoid use of this combination if possible. If the combination cannot be avoided, monitor closely for evidence of reduced response to the selective serotonin reuptake inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: Vortioxetine may enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Vortioxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors): May enhance the antiplatelet effect of Vortioxetine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Vortioxetine. Management: Consider alternatives to this drug combination. If combined, reduce the vortioxetine dose by half and monitor for signs and symptoms of bleeding and serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, autonomic instability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and seizures when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Venlafaxine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Venlafaxine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55504522"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Vortioxetine is approved for the treatment of unipolar major depressive disorder. If treatment for major depressive disorder is initiated for the first time in patients planning to become pregnant, vortioxetine is not a preferred antidepressant (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Vortioxetine may be associated with male and female treatment-emergent sexual dysfunction. Sexual dysfunction has been reported in males and females following vortioxetine use.</p></div>
<div class="block pri drugH1Div" id="F22560961"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information specific to vortioxetine use in pregnancy is limited (Shweiki 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Vortioxetine shares some properties of selective serotonin reuptake inhibitors (SSRIs); additionally, it modulates other serotoninergic activity. As a class, SSRIs have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for major depressive disorder is initiated for the first time during pregnancy, vortioxetine is not one of the preferred antidepressants (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).</p></div>
<div class="block brc drugH1Div" id="F22560963"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of vortioxetine in breast milk is available from 3 lactating women 1 to 6 months postpartum. Breast milk was sampled prior to and at intervals for 24 hours after the dose. All patients were at steady state and exclusively breastfeeding their infants:</p>
<p style="text-indent:-2em;margin-left:4em;">- Following a dose of vortioxetine 10 mg/day (n = 2), the maximum breast milk concentration was 13.89 ng/mL and occurred 7 hours after the dose. Based on this information, authors of the study calculated the relative infant dose (RID) of vortioxetine to be 1.1%, providing an estimated daily infant dose via breast milk of 0.0017 mg/kg/day, based on the weight-adjusted maternal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">- Following a dose of vortioxetine 20 mg/day (n = 1), the maximum breast milk concentration was 52.32 ng/mL and occurred 5 hours after the dose. Based on this information, the authors of the study calculated the RID of vortioxetine to be 1.7%, providing an estimated daily infant dose via breast milk of 0.0052 mg/kg/day (Marshall 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">- In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine shares some properties of selective serotonin reuptake inhibitors (SSRIs); additionally, it modulates other serotoninergic activity. Infants exposed to an SSRI via breast milk should be monitored for irritability and changes in sleep, feeding patterns, and behavior as well as growth and development (ABM [Sriraman 2015]; Sachs 2013; Weissman 2004; WFSBP [Bauer 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Maternal use of an SSRI during pregnancy may cause delayed lactogenesis (Marshall 2010); however, the underlying maternal illness may also influence this outcome (Grzeskowiak 2018). Untreated severe or chronic depression in the postpartum period also has negative effects on the mother and the infant (Slomian 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Psychotherapy or other nonmedication therapies are recommended for the initial treatment of mild depression in breastfeeding patients; however, antidepressant medication is recommended when psychotherapy is not an option or when symptoms are moderate to severe. If a specific SSRI was used effectively during pregnancy, it can be continued while breastfeeding if no contraindications exist (ABM [Sriraman 2015]). According to the manufacturer, the decision to breastfeed during vortioxetine therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. When first initiating an antidepressant in a patient who is breastfeeding, agents other than vortioxetine are preferred (ABM [Sriraman 2015]; CANMAT [MacQueen 2016]; Larsen 2015).</p></div>
<div class="block mop drugH1Div" id="F22560988"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; akathisia; signs/symptoms of serotonin syndrome and/or hyponatremia.</p></div>
<div class="block pha drugH1Div" id="F22560968"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits reuptake of serotonin (5-HT); also has agonist activity at the 5-HT<sub>1A</sub> receptor and antagonist activity at the 5-HT<sub>3</sub> receptor. Additionally, vortioxetine is a weak antagonist at 5-HT<sub>7</sub>­ and 5-HT<sub>1D</sub> receptors, as well as a partial agonist at 5-HT<sub>1B</sub> receptors (Bang-Andersen 2011; Kelliny 2015).</p></div>
<div class="block phk drugH1Div" id="F22560970"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 2,600 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic primarily through oxidation via CYP450 isoenzymes, primarily CYP2D6, and subsequent glucuronic acid conjugation to an inactive carboxylic acid metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 75%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~66 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 7 to 11 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (59%); feces (26%).</p></div>
<div class="block phksp drugH1Div" id="F54013109"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Obesity: In a study comparing the pharmacokinetic profile of vortioxetine in obese patients (BMI ≥35 kg/m<sup>2</sup> vs those with a BMI between 18.5 and 25 kg/m<sup>2</sup>), the mean elimination half-life was prolonged by 48% in obese patients (3.26 ± 1.22 days vs 2.21 ± 0.54 days) (Greenblat 2018).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671578"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Vorpix</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Vurtuoso</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Kelac</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Lupivor | Torvox | Trivoxetin | Vantaxa | Vipca | Vormind | Vorsero | Vortica | Vortidif | Vortiray | Voxigain | Voxitin | Xomet</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Trintellix</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Kelac</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Vorti</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Vortiox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Fonksera</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Brintellix</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Vivirum</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Brintellix | Trintogen | Vorellix | Vortioxetine adco | Vortioxetine lundbeck</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21767441">
<a name="21767441"></a>Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.<i> Int J Neuropsychopharmacol</i>. 2012;15(5):589‐600. doi:10.1017/S1461145711001027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/21767441/pubmed" id="21767441" target="_blank">21767441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee on Practice Bulletins - Obstetrics. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aydin.2019">
<a name="Aydin.2019"></a>Aydın EP, Dalkıran M, Özer OA, Karamustafalıoğlu KO. Hypomanic switch during vortioxetine treatment: a case report. <i>Psychiatry and Clinical Psychopharmacology. </i>2019;29(1):114-116. doi:10.1080/24750573.2018.1435602</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26864543">
<a name="26864543"></a>Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. <i>J Psychopharmacol</i>. 2016;30(3):242-252. doi:10.1177/0269881116628440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26864543/pubmed" id="26864543" target="_blank">26864543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21486038">
<a name="21486038"></a>Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. <i>J Med Chem.</i> 2011;54(9):3206-3221. doi:10.1021/jm101459g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/21486038/pubmed" id="21486038" target="_blank">21486038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385. doi:10.3109/15622975.2013.804195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135392">
<a name="32135392"></a>Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. <i>J Psychiatr Res</i>. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/32135392/pubmed" id="32135392" target="_blank">32135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867. Erratum in: <i>N Engl J Med</i>. 2007;356(23):2437. Erratum in: <i>N Engl J Med</i>. 2009;361(17):1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25641606">
<a name="25641606"></a>Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. <i>J Clin Pharmacol</i>. 2015;55(6):671-679. doi:10.1002/jcph.456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25641606/pubmed" id="25641606" target="_blank">25641606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28257449">
<a name="28257449"></a>Chen VC, Ng MH, Chiu WC, et al. Effects of selective serotonin reuptake inhibitors on glaucoma: a nationwide population-based study. <i>PLoS One</i>. 2017;12(3):e0173005. doi:10.1371/journal.pone.0173005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28257449/pubmed" id="28257449" target="_blank">28257449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24165478">
<a name="24165478"></a>Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? <i>Int J Clin Pract.</i> 2014;68(1):60‐82. doi:10.1111/ijcp.12350<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/24165478/pubmed" id="24165478" target="_blank">24165478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463440">
<a name="29463440"></a>Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction?. <i>Sex Med Rev</i>. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29463440/pubmed" id="29463440" target="_blank">29463440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21810375">
<a name="21810375"></a>Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. <i>Health Technol Assess</i>. 2011;15(28):1-202. doi:10.3310/hta15280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/21810375/pubmed" id="21810375" target="_blank">21810375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25693810">
<a name="25693810"></a>Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. <i>BMJ</i>. 2015;350:h517. doi: 10.1136/bmj.h517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25693810/pubmed" id="25693810" target="_blank">25693810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523917">
<a name="12523917"></a>Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. <i>Arch Intern Med</i>. 2003;163(1):59-64. doi:10.1001/archinte.163.1.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/12523917/pubmed" id="12523917" target="_blank">12523917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606952">
<a name="18606952"></a>de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. <i>Arch Gen Psychiatry</i>. 2008;65(7):795-803. doi:10.1001/archpsyc.65.7.795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/18606952/pubmed" id="18606952" target="_blank">18606952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25628505">
<a name="25628505"></a>D'Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. <i>P T</i>. 2015;40(1):36-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25628505/pubmed" id="25628505" target="_blank">25628505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31328985">
<a name="31328985"></a>D'Andrea G, De Ronchi D, Giaccotto L, Albert U. Vortioxetine treatment-emergent mania in the elderly: a case report. <i>Australas Psychiatry</i>. 2019;27(4):413. doi:10.1177/1039856219839471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31328985/pubmed" id="31328985" target="_blank">31328985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28245753">
<a name="28245753"></a>de Boer MK, Schoevers RA. Methodological differences as an explanation for the divergent results of studies on sexual dysfunction related to the use of vortioxetine. <i>J Psychopharmacol</i>. 2017;31(3):389-390. doi:10.1177/0269881116681520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28245753/pubmed" id="28245753" target="_blank">28245753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi: 10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15746956">
<a name="15746956"></a>Ezra DG, Storoni M, Whitefield LA. Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment. <i>Eye (Lond)</i>. 2006;20(1):128-129. doi:10.1038/sj.eye.6701815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/15746956/pubmed" id="15746956" target="_blank">15746956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30016772">
<a name="30016772"></a>Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. <i>Psychother Psychosom</i>. 2018;87(4):195-203. doi:10.1159/000491524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30016772/pubmed" id="30016772" target="_blank">30016772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72-81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28333546">
<a name="28333546"></a>Findling RL, Robb AS, DelBello M, et al. Pharmacokinetics and safety of vortioxetine in pediatric patients. <i>J Child Adolesc Psychopharmacol</i>. 2017;27(6):526-534. doi:10.1089/cap.2016.0155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28333546/pubmed" id="28333546" target="_blank">28333546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648376">
<a name="31648376"></a>Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. <i>Acta Psychiatr Scand</i>. 2020;141(1):21-33. doi:10.1111/acps.13120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31648376/pubmed" id="31648376" target="_blank">31648376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28554948">
<a name="28554948"></a>Gabriel M, Sharma V. Antidepressant discontinuation syndrome. <i>CMAJ</i>. 2017;189(21):E747. doi:10.1503/cmaj.160991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28554948/pubmed" id="28554948" target="_blank">28554948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27773479">
<a name="27773479"></a>Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-generation antidepressants and hyponatremia risk: a population-based cohort study of older adults. <i>Am J Kidney Dis</i>. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27773479/pubmed" id="27773479" target="_blank">27773479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29596146">
<a name="29596146"></a>Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine disposition in obesity: potential implications for patient safety. <i>J Clin Psychopharmacol</i>. 2018;38(3):172-179. doi:10.1097/JCP.0000000000000861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29596146/pubmed" id="29596146" target="_blank">29596146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi: 10.1080/15622975.2017.1384850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522259">
<a name="29522259"></a>Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. <i>Br J Clin Pharmacol</i>. 2018;84(6):1373-1379. doi:10.1111/bcp.13575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29522259/pubmed" id="29522259" target="_blank">29522259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59. doi:10.31887/DCNS.2007.9.1/dhalperin<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2021a">
<a name="Hirsch.2021a"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2021b">
<a name="Hirsch.2021b"></a>Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35029863">
<a name="35029863"></a>Işik M, Kurhan F, Ülkevan T, Özdemir PG. Vortioxetine-induced amenorrhea: a case report. <i>Clin Neuropharmacol</i>. 2022;45(1):7-8. doi:10.1097/WNF.0000000000000490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/35029863/pubmed" id="35029863" target="_blank">35029863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26020712">
<a name="26020712"></a>Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. <i>Int Clin Psychopharmacol</i>. 2015a;30(5):255-264. doi:10.1097/YIC.0000000000000081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26020712/pubmed" id="26020712" target="_blank">26020712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26331383">
<a name="26331383"></a>Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. <i>J Sex Med</i>. 2015b;12(10):2036-2048. doi:10.1111/jsm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26331383/pubmed" id="26331383" target="_blank">26331383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26575433">
<a name="26575433"></a>Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. <i>CNS Spectr</i>. 2016;21(5):367-378. doi:10.1017/S1092852915000553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26575433/pubmed" id="26575433" target="_blank">26575433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31010445">
<a name="31010445"></a>Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. <i>CNS Spectr</i>. 2020;25(1):50-63. doi:10.1017/S1092852919000750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31010445/pubmed" id="31010445" target="_blank">31010445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31405765">
<a name="31405765"></a>Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: a randomized, controlled trial. <i>J Sex Med</i>. 2019;16(10):1638-1649. doi:10.1016/j.jsxm.2019.06.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31405765/pubmed" id="31405765" target="_blank">31405765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi: 10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Katona.1">
<a name="Katona.1"></a>Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. <i>Int Clin Psychopharmacol</i>. 2012;27(4):215-223.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26316764">
<a name="26316764"></a>Kelliny M, Croarkin PE, Moore KM, Bobo WV. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. <i>Ther Clin Risk Manag</i>. 2015;11:1193-1212. doi:10.2147/TCRM.S55313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26316764/pubmed" id="26316764" target="_blank">26316764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27194321">
<a name="27194321"></a>Leth-Møller KB, Hansen AH, Torstensson M, et al. Antidepressants and the risk of hyponatremia: a Danish register-based population study. <i>BMJ Open</i>. 2016;6(5):e011200. doi:10.1136/bmjopen-2016-011200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27194321/pubmed" id="27194321" target="_blank">27194321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31199210">
<a name="31199210"></a>Mahableshwarkar AR, Affinito J, Reines EH, Xu J, Nomikos G, Jacobsen PL. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. <i>CNS Spectr</i>. 2020;25(3):352-362. doi:10.1017/S109285291900097X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31199210/pubmed" id="31199210" target="_blank">31199210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25575488">
<a name="25575488"></a>Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. <i>Psychopharmacology (Berl)</i>. 2015;232(12):2061-2070. doi:10.1007/s00213-014-3839-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25575488/pubmed" id="25575488" target="_blank">25575488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19965920">
<a name="19965920"></a>Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. <i>J Clin Endocrinol Metab</i>. 2010;95(2):837-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/19965920/pubmed" id="19965920" target="_blank">19965920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33861632">
<a name="33861632"></a>Marshall K, Datta P, Rewers-Felkins K, Krutsch K, Baker T, Hale TW. Transfer of the serotonin modulator vortioxetine into human milk: a case series. <i>Breastfeed Med</i>. Published online April 16, 2021. doi:10.1089/bfm.2021.0074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/33861632/pubmed" id="33861632" target="_blank">33861632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170040">
<a name="30170040"></a>Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30170040/pubmed" id="30170040" target="_blank">30170040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26994277">
<a name="26994277"></a>Maud C. Vortioxetine in bipolar depression induces a mixed/manic switch. <i>Australas Psychiatry</i>. 2016;24(2):206-207. doi:10.1177/1039856215614986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26994277/pubmed" id="26994277" target="_blank">26994277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923970">
<a name="29923970"></a>Mazza MG, Rossetti A, Botti ER, Clerici M. Vortioxetine overdose in a suicidal attempt: a case report. <i>Medicine (Baltimore)</i>. 2018;97(25):e10788. doi:10.1097/MD.0000000000010788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29923970/pubmed" id="29923970" target="_blank">29923970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29238196">
<a name="29238196"></a>McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2913-2919. doi:10.2147/NDT.S150589<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29238196/pubmed" id="29238196" target="_blank">29238196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24566587">
<a name="24566587"></a>Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). <i>Osteoporos Int</i>. 2014;25(5):1473-1481. doi:10.1007/s00198-014-2649-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/24566587/pubmed" id="24566587" target="_blank">24566587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21453380">
<a name="21453380"></a>Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. <i>J Am Geriatr Soc</i>. 2011;59(4):577-585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/21453380/pubmed" id="21453380" target="_blank">21453380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30407100">
<a name="30407100"></a>Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. <i>J Womens Health (Larchmt)</i>. 2019;28(3):331-338. doi:10.1089/jwh.2018.7319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30407100/pubmed" id="30407100" target="_blank">30407100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37230747">
<a name="37230747"></a>O'Brien TM. Acute eosinophilic pneumonia-like syndrome post-initiation of vortioxetine. <i>BMJ Case Rep</i>. 2023;16(5):e254254. doi:10.1136/bcr-2022-254254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/37230747/pubmed" id="37230747" target="_blank">37230747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract.</i> 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29917334">
<a name="29917334"></a>Ong CY, Vasanwala FF. Diaphoresis: a presentation of serotonin syndrome from vortioxetine. <i>Prim Care Companion CNS Disord</i>. 2018;20(3):17l02191. doi:10.4088/PCC.17l02191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29917334/pubmed" id="29917334" target="_blank">29917334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28844296">
<a name="28844296"></a>Pelayo-Terán JM, Martínez-Pérez MM, Zapico-Merayo Y. Safety in the use of antidepressants: vortioxetine-induce hyponatremia in a case report. <i>Rev Psiquiatr Salud Ment</i>. 2017;10(4):219-220. doi:10.1016/j.rpsm.2017.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28844296/pubmed" id="28844296" target="_blank">28844296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137. doi: 10.1007/s00198-012-2015-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26032210">
<a name="26032210"></a>Rauma PH, Pasco JA, Berk M, et al. The association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in men. <i>J Musculoskelet Neuronal Interact</i>. 2015;15(2):177-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26032210/pubmed" id="26032210" target="_blank">26032210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156519">
<a name="26156519"></a>Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. <i>BMJ</i>. 2015;351:h3190. doi:10.1136/bmj.h3190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26156519/pubmed" id="26156519" target="_blank">26156519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci TherR</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613. doi: 10.1016/j.bone.2012.05.018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31433340">
<a name="31433340"></a>Romigi A, Vitrani G, Caccamo M, Centonze D. Restless legs syndrome related to vortioxetine: a case report. <i>J Clin Psychopharmacol</i>. 2019;39(5):514-516. doi:10.1097/JCP.0000000000001092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31433340/pubmed" id="31433340" target="_blank">31433340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33463081">
<a name="33463081"></a>Shweiki S, Diav-Citrin O. Pregnancy outcome after first trimester exposure to vortioxetine: a case series. <i>Birth Defects Res</i>. Published online January 19, 2021. doi:10.1002/bdr2.1864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/33463081/pubmed" id="33463081" target="_blank">33463081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34064611">
<a name="34064611"></a>Siwek M, Chrobak AA, Gorostowicz A, Krupa AJ, Dudek D. Withdrawal symptoms following discontinuation of vortioxetine-retrospective chart review. <i>Pharmaceuticals (Basel)</i>. 2021;14(5):451. doi:10.3390/ph14050451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/34064611/pubmed" id="34064611" target="_blank">34064611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035856">
<a name="31035856"></a>Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. <i>Womens Health (Lond)</i>. 2019;15:1745506519844044. doi:10.1177/1745506519844044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31035856/pubmed" id="31035856" target="_blank">31035856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30964616">
<a name="30964616"></a>Sobieraj DM, Baker WL, Martinez BK, et al. Adverse effects of pharmacologic treatments of major depression in older adults [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019. Report No.: 19-EHC011-EF.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30964616/pubmed" id="30964616" target="_blank">30964616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28273272">
<a name="28273272"></a>Sobreira G, Oliveira J, Brissos S. Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder. <i>Braz J Psychiatry</i>. 2017;39(1):86. doi:10.1590/1516-4446-2016-2113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28273272/pubmed" id="28273272" target="_blank">28273272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17088502">
<a name="17088502"></a>Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. <i>Arch Gen Psychiatry</i>. 2006;63(11):1217-23. doi:10.1001/archpsyc.63.11.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/17088502/pubmed" id="17088502" target="_blank">17088502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takeda.1">
<a name="Takeda.1"></a>Trintellix (vortioxetine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lundbeck.1">
<a name="Lundbeck.1"></a>Trintellix (vortioxetine) [product monograph]. St-Laurent, Quebec, Canada: Lundbeck Canada Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31469980">
<a name="31469980"></a>Uljon S, Kataria Y, Flood JG. Vortioxetine use may cause false positive immunoassay results for urine methadone.<i> Clin Chim Acta.</i> 2019;499:1-3. doi:10.1016/j.cca.2019.08.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/31469980/pubmed" id="31469980" target="_blank">31469980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26126579">
<a name="26126579"></a>Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. <i>Osteoporos Int</i>. 2016;27(1):57-63. doi:10.1007/s00198-015-3213-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/26126579/pubmed" id="26126579" target="_blank">26126579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27495351">
<a name="27495351"></a>Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? <i>Curr Osteoporos Rep</i>. 2016;14(5):211-218. doi:10.1007/s11914-016-0322-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/27495351/pubmed" id="27495351" target="_blank">27495351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry</i>. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30278181">
<a name="30278181"></a>Wiciński M, Kaluzny BJ, Liberski S, Marczak D, Seredyka-Burduk M, Pawlak-Osińska K. Association between serotonin-norepinephrine reuptake inhibitors and acute angle closure: what is known? <i>Surv Ophthalmol</i>. 2019;64(2):185-194. doi:10.1016/j.survophthal.2018.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/30278181/pubmed" id="30278181" target="_blank">30278181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953843">
<a name="28953843"></a>Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. <i>Psychiatr Danub</i>. 2017;29(suppl 3):629-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/28953843/pubmed" id="28953843" target="_blank">28953843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al. The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol</i>. 2009;114(3):703-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25562777">
<a name="25562777"></a>Zhang J, Mathis MV, Sellers JW, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. <i>J Clin Psychiatry</i>. 2015;76(1):8-14. doi:10.4088/JCP.14r09164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/25562777/pubmed" id="25562777" target="_blank">25562777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29893371">
<a name="29893371"></a>Zhou N, Zhao JX, Zhu YN, Zhang P, Zuo Y. Acute angle-closure glaucoma caused by venlafaxine. <i>Chin Med J (Engl)</i>. 2018;131(12):1502-1503. doi:10.4103/0366-6999.233952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vortioxetine-drug-information/abstract-text/29893371/pubmed" id="29893371" target="_blank">29893371</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 91014 Version 289.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
